7-5997415-G-T
Variant summary
Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PM1
The NM_000535.7(PMS2):c.714C>A(p.Ser238Arg) variant causes a missense change. The variant allele was found at a frequency of 0.0000193 in 1,553,640 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S238N) has been classified as Uncertain significance.
Frequency
Consequence
NM_000535.7 missense
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- Lynch syndrome 4Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 4Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- ovarian cancerInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- Muir-Torre syndromeInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- prostate cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000819 AC: 11AN: 134326Hom.: 0 Cov.: 29 show subpopulations
GnomAD2 exomes AF: 0.0000302 AC: 7AN: 231926 AF XY: 0.0000319 show subpopulations
GnomAD4 exome AF: 0.0000134 AC: 19AN: 1419314Hom.: 0 Cov.: 25 AF XY: 0.0000141 AC XY: 10AN XY: 708272 show subpopulations ⚠️ The allele balance in gnomAD version 4 Exomes is significantly skewed from the expected value of 0.5.
GnomAD4 genome AF: 0.0000819 AC: 11AN: 134326Hom.: 0 Cov.: 29 AF XY: 0.000108 AC XY: 7AN XY: 64700 show subpopulations
ClinVar
Submissions by phenotype
Lynch syndrome 4 Uncertain:6
- -
- -
The PMS2 c.714C>A (p.Ser238Arg) missense change has a maximum subpopulation frequency of 0.031% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/variant/7-6037046-G-T). Six of seven in silico tools predict a deleterious effect of this variant on protein function (PP3), but to our knowledge these predictions have not been confirmed by functional assays. To our knowledge, this variant has not been reported in individuals with Lynch syndrome or constitutional mismatch repair deficiency. In summary, this variant meets criteria to be classified as of uncertain significance based on the ACMG/AMP criteria: PP3. -
- -
This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
not provided Uncertain:3
- -
The PMS2 c.714C>A (p.Ser238Arg) variant has been reported in the published literature in individuals with breast cancer (PMID: 35534704 (2022), 35264596 (2022)). This variant has also been identified in a cohort of individuals with prostate cancer and reportedly healthy individuals (PMID: 32832836 (2020)). Assessment of experimental evidence regarding the effect of this variant on protein function suggests it has no effect relevant to disease (PMID: 35189042 (2022)). The frequency of this variant in the general population, 0.00031 (7/22924 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Published functional studies suggest no damaging effect: no significant impact on mismatch repair (MMR) activity (PMID: 35189042); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 11574484, 35189042, 35264596, 35534704) -
Lynch syndrome Uncertain:2
- -
This missense variant replaces serine with arginine at codon 238 of the PMS2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Functional studies have shown that this variant caused increased protein expression and had no significant impact on mismatch repair or ATPase activity compared to wild type protein (PMID: 35189042). This variant has been reported in an individual affected with breast cancer (DOI: 10.1101/2021.04.15.21255554v2). This variant has been identified in 9/258576 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:2
The p.S238R variant (also known as c.714C>A), located in coding exon 7 of the PMS2 gene, results from a C to A substitution at nucleotide position 714. The serine at codon 238 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
This missense variant replaces serine with arginine at codon 238 of the PMS2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Functional studies have shown that this variant caused increased protein expression and had no significant impact on mismatch repair or ATPase activity compared to wild type protein (PMID: 35189042). This variant has been reported in an individual affected with breast cancer (DOI: 10.1101/2021.04.15.21255554v2). This variant has been identified in 9/258576 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at